List of Tables
Table 1. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Competitive Situation by Manufacturers in 2024
Table 4. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) of Key Manufacturers (2020-2025)
Table 5. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Average Price (US$/Box) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Product Type & Application
Table 12. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2020-2025) & (Box)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2020-2025)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2026-2031) & (Box)
Table 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2026-2031)
Table 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2020-2025)
Table 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2026-2031)
Table 25. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) & (Box)
Table 27. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2026-2031) & (Box)
Table 28. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) & (Box)
Table 32. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2026-2031) & (Box)
Table 33. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2020-2025) & (Box)
Table 37. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2026-2031) & (Box)
Table 38. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) & (Box)
Table 42. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2026-2031) & (Box)
Table 43. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) & (Box)
Table 47. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2026-2031) & (Box)
Table 48. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2020-2025)
Table 51. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Type (2026-2031)
Table 52. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2020-2025)
Table 53. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2026-2031)
Table 54. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2020-2025)
Table 57. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2026-2031)
Table 58. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2020-2025)
Table 59. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2026-2031)
Table 60. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Application (2020-2025)
Table 61. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box) by Application (2026-2031)
Table 62. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2020-2025)
Table 63. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2026-2031)
Table 64. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2020-2025)
Table 67. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2026-2031)
Table 68. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2020-2025)
Table 69. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2026-2031)
Table 70. Yongshun Creatures Company Information
Table 71. Yongshun Creatures Description and Business Overview
Table 72. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 73. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 74. Yongshun Creatures Recent Developments/Updates
Table 75. Keqian Biology Company Information
Table 76. Keqian Biology Description and Business Overview
Table 77. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 78. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 79. Keqian Biology Recent Developments/Updates
Table 80. Boehringer Ingelheim Company Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 83. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Sinovet Company Information
Table 86. Sinovet Description and Business Overview
Table 87. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 88. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 89. Sinovet Recent Developments/Updates
Table 90. Elanco Company Information
Table 91. Elanco Description and Business Overview
Table 92. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 93. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 94. Elanco Recent Developments/Updates
Table 95. MSD Company Information
Table 96. MSD Description and Business Overview
Table 97. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 98. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 99. MSD Recent Developments/Updates
Table 100. Cahic Company Information
Table 101. Cahic Description and Business Overview
Table 102. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 103. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 104. Cahic Recent Developments/Updates
Table 105. Ringpu Company Information
Table 106. Ringpu Description and Business Overview
Table 107. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 108. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 109. Ringpu Recent Developments/Updates
Table 110. Baoling Company Information
Table 111. Baoling Description and Business Overview
Table 112. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 113. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 114. Baoling Recent Developments/Updates
Table 115. Jizhong Company Information
Table 116. Jizhong Description and Business Overview
Table 117. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 118. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 119. Jizhong Recent Developments/Updates
Table 120. Dahuanong Company Information
Table 121. Dahuanong Description and Business Overview
Table 122. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 123. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 124. Dahuanong Recent Developments/Updates
Table 125. Hayao Company Information
Table 126. Hayao Description and Business Overview
Table 127. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 128. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 129. Hayao Recent Developments/Updates
Table 130. Pulike Biology Company Information
Table 131. Pulike Biology Description and Business Overview
Table 132. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 133. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 134. Pulike Biology Recent Developments/Updates
Table 135. Tecon Company Information
Table 136. Tecon Description and Business Overview
Table 137. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2020-2025)
Table 138. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product
Table 139. Tecon Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 143. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers List
Table 144. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends
Table 145. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
Table 146. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
Table 147. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live
Figure 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Type: 2024 & 2031
Figure 4. TJM-F92 Strain Product Picture
Figure 5. GDr180 Strain Product Picture
Figure 6. JXA1-R Strain Product Picture
Figure 7. Other Product Picture
Figure 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Application: 2024 & 2031
Figure 10. Farms
Figure 11. Individual
Figure 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size (2020-2031) & (US$ Million)
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (2020-2031) & (Box)
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Average Price (US$/Box) & (2020-2031)
Figure 16. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Report Years Considered
Figure 17. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Manufacturers in 2024
Figure 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Players: Market Share by Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in 2024
Figure 20. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2020-2031)
Figure 23. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2020-2031)
Figure 24. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2020-2031)
Figure 27. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2020-2031)
Figure 28. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2020-2031)
Figure 35. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Indonesia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Thailand Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Malaysia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2020-2031)
Figure 45. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Type (2020-2031)
Figure 55. Global Revenue Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Type (2020-2031)
Figure 56. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Type (2020-2031)
Figure 57. Global Sales Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Application (2020-2031)
Figure 58. Global Revenue Market Share of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Application (2020-2031)
Figure 59. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price (US$/Box) by Application (2020-2031)
Figure 60. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
